Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,411 matching trials from the live ClinicalTrials.gov search.
Conditions
Hematologic Malignancy, Myeloproliferative Disorder
Interventions
Isavuconazole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 74 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, cytarabine, fludarabine phosphate, methotrexate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Chronic Myelogenous Leukemia
Interventions
Zileuton (Zyflo®) Dasatinib (Sprycel®), Dosing with Zileuton/Dasatinib in CML, Daily dosing of Zileuton/Dasatinib, Daily dosing with Zileuton/Dasatinib for CML
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Melanoma, Ovarian Cancer, Sarcoma, Bone, CNS-Spinal CD/MEMBR, NOS, Lymph Nodes, Soft Tissue
Interventions
IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Hematologic Malignancy
Interventions
FLT PET/CT, MRI
Radiation · Device
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Other Acute Leukemias
Interventions
Unmanipulated Umbilical Cord Blood (UCB), AB-110
Biological
Lead sponsor
Angiocrine Bioscience
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Duarte, California • Aurora, Colorado • New York, New York
Conditions
Leukemia
Interventions
filgrastim, recombinant interferon alfa, busulfan, cytarabine, etoposide, hydroxyurea, idarubicin, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
15 Years to 65 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Hackensack, New Jersey • Red Bank, New Jersey
Conditions
Acute Lymphoblastic Leukemia/Lymphoma, Myelodysplasia, Acute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Chronic Myelogenous Leukemia
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Up to 22 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
32
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Conditions
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Danvatirsen, Danvatirsen + Venetoclax
Drug · Combination Product
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
The Bronx, New York • Houston, Texas
Conditions
Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions
extracorporeal photopheresis
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer in Inherited Bone Marrow Failure Syndromes

NCT00027274
Conditions
Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
Interventions
PR1 leukemia peptide vaccine, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Bone Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Intraoperative Nerve Monitoring, Surgical Procedure, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Duarte, California
Active, not recruiting Phase 2 Interventional

Osteosarcoma Maintenance Therapy With OST31-164

NCT04974008
Conditions
Bone Cancer
Interventions
OST31-164
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
12 Years to 39 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Los Angeles, California • Orange, California • San Diego, California + 18 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more
Conditions
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
Interventions
CB-5339
Drug
Lead sponsor
Cleave Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Fairway, Kansas • New York, New York + 3 more
Conditions
Metastatic Breast Cancer
Interventions
High-dose chemotherapy
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2002
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Pediatric ALL, Pediatric Lymphoma, Bone Loss, Metabolic Syndrome, Habitual Physical Activity, Precursor Cell Lymphoblastic Leukemia, Lymphoma, Leukemia, Lymphoid Leukemia, Pediatric, Osteoporosis, Osteoporosis Risk
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 18 Years
Enrollment
40 participants
Timeline
2020 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation
Interventions
liposomal daunorubicin citrate, semaxanib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas